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Introduction: Whether the results of cancer clinical trials conducted 
outside the United States (USA) can be directly extrapolated to North 
American populations is a question of increasing importance due to 
recent trends toward globalization of the clinical trials process. Differ-
ences in outcomes between clinical trials evaluating the same treatment 
regimen can obviously be explained by many factors, including vari-
ance in patient demographics, trial design and conduct, and treatment 
itself. In regard to divergence of results in trials performed in different 
parts of the world, the additional question of racial and/our ethnic-re-
lated genetic differences must be considered. Approximately 7 years 
ago, the Southwest Oncology Group (SWOG) established an ongo-
ing collaboration with Japanese lung cancer investigators, in order to 
provide a forum for exchange of research data, to facilitate standariza-
tion of clinical trial design and conduct, and to establish areas for joint 
collaboration, as described below.
Purpose: To explore whether population-related pharmacogenomics 
contribute to differences in patient outcomes between clinical trials 
performed in Japan and the USA, given similar patient demographics 
and treatment.
Patients and Methods: We prospectively designed and conducted 
three phase III trials (FACS, LC03, S0003) in advanced stage NSCLC, 
with similar eligibility, staging and treatment with a “common arm” of 
paclitaxel-carboplatin. Genomic DNA was prospectively collected from 
patients in LC03 (N=78, 37 on common arm) & S0003 (N=78) receiv-
ing paclitaxel (225mg/m2) & carboplatin (AUC 6). Analysis for geno-
typic variants of CYP3a4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, 
ERCC2 was performed by pyrosequencing, & results assessed by Cox 
model for survival/PFS & logistics regression for response/toxicity.
Results: Clinical results were similar in the 2 Japanese trials, and 
signiﬁcantly different from the USA trial in survival, neutropenia, and 
febrile neutropenia. There was a signiﬁcant difference between Japan & 
USA patients in genotypes: CYP3A4*1b (p=.01), CYP3A5*3c (p=.03), 
ERCC2 k751q (p < .001), and CYP2C8 r139k (p=.01). Genotypic 
correlations were observed between CYP3A4*1b for PFS (HR 2.75, 
1.06-7.08, p=.04) & ERCC2 k751q for response (HR 0.33, 0.13-0.84, 
p=.02). There were no other statistically signiﬁcant associations. For 
grade 4 neutropenia, the HR for ABCB1 3425c->T was 1.84 (0.77-
4.48), p=.19. The low number of febrile neutropenia events within this 
data set precluded assessment of this parameter. 
Conclusions: Differences in allelic distribution for genes involved in 
paclitaxel disposition or DNA repair were observed between Japanese 
& USA patients. Genotype-associated correlations were present for 
PFS (CYP3A4*1b) & response (ERCC2 k751q), but not for neutrope-
nia (p=.19). The small sample size limits interpretation of these data. 
Further studies based on this common arm approach are warranted for 
the prospective study of population-related PGs where ethnical/racial 
differences in anti-neoplastic drug disposition are anticipated.
We hypothesized that population-related pharmacogenomics plays a 
role in explaining outcome differences between trials evaluating similar 
treatment regimens in advanced stage NSCLC demonstrate similarities 
or differences between patient characteristics and outcomes in Japanese 
and U.S. trials in advanced stage NSCLC under the inﬂuence of the 
same regimen. 
To provide the basis for standardization of study design and conduct in 
order to facilitate interpretation of future trials, and to provide the ﬁrst 
step to joint NCI sponsored studies in lung cancer between Japanese 
and U.S. investigators.
We have previously reported differences in outcomes (increased 
survival, neutropenia & febrile neutropenia) in Japanese versus US 
patients (pts) treated with a paclitaxel-carboplatin “common arm” in 
a prospectively designed fashion in 3 phase III trials (FACS, LC03, 
S0003) in advanced NSCLC (Gandara, ASCO 05 & Crowley, ASCO 
06). We hypothesized that these ﬁndings were due in part to PG altera-
tions in paclitaxel disposition.
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The JCOG 9511 study demonstrated that irinotecan + cisplatin therapy 
yielded signiﬁcantly better survival than etoposide + cisplatin in exten-
sive small cell lung cancer. On the other hand, Hanna reported no dif-
ference in response rate, median time-to-progression or overall survival 
in a second study that involved 331 ED-SCLC pts and compared two 
regimens, although irinotecan + cisplatin was given weekly. SWOG 
0124 used exactly the same schedule of administration of all anticancer 
drugs as JCOG 9511, and the toxicities in the 554 pts were compared 
with those of the patients in JCOG 9511. The results showed that the 
frequency of neutropenia, leucopenia, and anemia was signiﬁcantly 
higher in the JCOG 9511 patients.
Irinotecan + cisplatin is also one of the standard doublets used to treat 
NSCLC in Japan, and it yields a response rate, time to progression, and 
survival equivalent to other platinum doublets in NSCLC.
Topotecan is another topoisomerase I inhibitor. In a randomized trial in 
784 patients the combination of oral topotecan with cisplatin for 5 days 
was found not to be superior to etoposide and cisplatin. In the United 
States, topotecan has been used as a standard regimen for second line 
treatment of ED-SCLC. In Japan the JCOG just started an RCT of 
topotecan vs weekly irinotecan + etoposide + cisplatin.
Camptothecin analogues are detoxiﬁed by glucuronization. The SNP 
variability of UGT1A1 contributes to differences in the efﬁcacy or 
toxicity of cancer therapy. In the United States UGT1A1 PGx added “A 
reduction in the starting dose by at least one level should be considered 
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for patients known to be homozygous for the UGT1A1*28 allele” to 
the label of irinotecan.
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Overview
COX-2, the enzyme that converts arachidonic acid to prostaglandins, 
is over-expressed in a variety of malignancies including non-small cell 
lung cancer (NSCLC). Inhibition of COX- 2 has resulted in reduced 
proliferation of cancer cell in vitro(Asktorab, PAACR 2001). The drug 
has demonstrated unequivocal activity in prevention of colorectal 
neoplasia (polyps) in patients with familial adenomatous polyposis 
(Steinbach NEJM 2000). Khuri and colleagues have recently demon-
strated that over-expression of COX-2 is common in non-small cell 
lung cancer and associated with poor prognosis (CCR 2001). A recent 
meta-analysis found a trend for reduced survival, but this did not 
achieve statistical signiﬁcance. Nearly 80% of NSCLC overexpress 
COX-2 (Mascauz BJC, 2006). COX-2 overexpression occurs not only 
in the tumor cells but also in the tumor vasculature (Wolff, Can Res 
1998). Therefore, selective COX-2 inhibitors such as celecoxib have 
the potential to inhibit tumor angiogenesis and metasases and might 
serve as ideal agents for long term maintenance therapy. 
Clinical Experience with COX-2 inhibition in Lung Cancer
Despite the wealth of evidence supporting the potential clinical beneﬁt 
of COX-2 inhibition, the results to date have been somewhat disap-
pointing. Carboplatin/paclitaxel and celecoxib have been combined 
at full doses in a preoperative study of Stage I and II NSCLC with no 
evidence of overlapping toxicities. Altorki demonstrated that intratu-
moral levels of COX-2 increase in response to carboplatin/paclitaxel 
chemotherapy (CCR 2005). Hence, concurrent treatment with a COX-2 
inhibitor has the potential to abrogate this adverse effect. A randomized 
phase II trial adding celecoxib to either docetaxel/irinotecan or gem-
citabine/irinotecan in second line therapy (n=132), failed to demon-
strate an advantage for celecoxib (Lillenbaum, JCO 2006). 
Cancer and Leukemia Group B (CALGB) trial 30203 was developed to 
test the concept of eicosanoid inhibition, including COX-2 inhbition, in 
advanced lung cancer. The concept of single vs. double pathway inhibi-
tion was tested with inhibitors of COX-2 and 5-lipoxygenase (5-LOX) 
as both single agents and in combination. The overall results of the 
study were negative. 140 patients were entered and 136 were eligible 
and treated . There was no beneﬁt in terms of PFS or OS between the 
arms (Edelman, Proc ASCO, 2006). 107 tissue blocks were submitted 
and 83 were adequate for immunohistochemistry analysis. The study 
demonstrated that moderate to high COX-2 expression was a negative 
prognostic marker for patients receiving chemotherapy who did not 
receive celecoxib ( index > 4, HR = 2.683, p= .018; index =9, HR = 
4.155, p= .009). However, COX-2 expression was a positive predictive 
factor for patients receiving celecoxib + chemotherapy (Edelman,JTO 
2006). Patients with moderate to high COX-2 expression (index > 
4) who received celecoxib had better survival. There was a trend for 
patients treated with celecoxib who did not overexpress COX-2 to 
have a worse outcome (p=.178). A multivariate analysis conﬁrmed the 
independent interaction of COX-2 with celecoxib and survival. 5-LOX 
expression was neither prognostic nor predictive of outcome.
The possible adverse effect for those who received celecoxib and did 
not overexpress COX-2 may explain the recent negative trials utilizing 
celecoxib in lung and other malignancies as any positive effect in the 
COX-2 expressing patients may have been obscured by the negative 
effects of the agent on patients whose tumors did not express COX-2. 
Interestingly, a similar ﬁnding of the importance of COX-2 expres-
sion and beneﬁt from COX-2 inhibition has been reported in renal 
cell carcinoma in which a small study (n=25) of interferon alpha + 
celecoxib demonstrated the best results for the COX-2 overexpressing 
patients despite the known negative prognostic implications of COX-2 
expression in renal cell carcinoma and that these patients demonstrated 
several other negative prognostic variables as well(Rini Cancer 2005). 
Only patients who overexpressed COX-2 demonstrated measurable 
response and increased time to progression. Importantly, there is sup-
porting data from other lung cancer studies. Csiki has demonstrated 
that levels of a COX-2 dependent metabolite, PGE-2 correlated with 
survival in patients who were treated with celecoxib + docetaxel as 
second line chemotherapy(CCR, 2005). Fidler evaluated celecoxib + 
erlotinib in second line therapy (n=21) and found that patients with 
COX-2 overexpression had signiﬁcantly longer survival than those that 
did not express COX-2 (IASLC, Santa Monica, 2007). 
Future Directions
The future of COX-2 directed therapy in NSCLC will require that se-
lective trials be performed. As noted above, approximately 35% of pa-
tients with advanced NSCLC appear to demonstrate signiﬁcant beneﬁt 
from the addition of a selective COX-2 inhibitor to standard chemo-
therapy. Adoption of this strategy will require prospective, adequately 
powered clinical trials. Inherent in the design of such a trial is that a 
large number of patients will need to be screened before enrollment. 
In the case of COX-2, approximately 35% of patients with advanced 
NSCLC would be potential candidates for entry. A trial evaluating the 
role of COX-2 inhibition has been proposed by the CALGB. While 
the concept that biological characteristics for entry onto clinical trials 
has long been accepted in breast cancer (e.g. hormone receptor status, 
Her2/neu) and hematologic malignancies (t 15;17 etc), it is a relatively 
new concept for lung cancer studies and has met with surprising resis-
tance. This resistance appears to be based upon the limited amount of 
pathologic material available in many cases (i.e. diagnosis based upon 
ﬁne needle aspiration). 
Interestingly, the COX-2 inhibitors have important biological actions 
in addition to COX-2 inhibition. These include increased expression 
of death receptors, particularly DR5, and therefore may potentially 
demonstrate synergistic interactions with TRAIL agonists currently 
in development(Liu JNCI 2004). In addition, there are signiﬁcant im-
muomodulating effects of these agents indicating a potential future role 
in combination with the emerging area of vaccine development(Haas, 
CCR 2006). Of note, other selective COX-2 inhibitors are also under 
development as cancer speciﬁc agents rather than as analgesic or anti-
inﬂamatory drugs. 
In summary, while the results of COX-2 inhibition in addition to stan-
dard therapies in the general population has been disappointing, there is 
emerging evidence that these agents may yet play a signiﬁcant role in a 
selected population of patients. 
